Thrombin/Antithrombin-Iii Complex Level as Early Predictor of Reocclusion After Successful Thrombolysis

Gulba, DietrichC.; Barthels, Monika; Reil, Gert‐Hinrich; P, Lichtlen

doi:10.1016/s0140-6736(88)90021-9

Cited by 51 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…19 The reason for this is activated platelets after administration of tenecteplase. 20 Several clinical studies (ie, ASSENT-4, 12 PRAGUE-2 21 and CAPTIM 22 ) have shown that the time from onset to t-PA injection is important (within 2-3 h) for effectiveness of this type of treatment. In particular, the CAPTIM study comparing long-term results of prior t-PA administration and primary PCI, recently reported that the long-term prognosis in patients with prior t-PA administration within 2 h is superior to that in those with primary PCI, and suggested that prior administration of t-PA in the super acute phase is very important.…”

Section: Prescription Before Admission (%)mentioning

confidence: 99%

Comparison of Long-Term Prognostic Evaluation Between Pre-Intervention Thrombolysis and Primary Coronary Intervention: A Prospective Randomized Trial - Five-Year Results of the IMPORTANT Study -

Itoh

Fukami

Suzuki

et al. 2010

Circ J

View full text Add to dashboard Cite

Section: Prescription Before Admission (%)mentioning

confidence: 99%

Comparison of Long-Term Prognostic Evaluation Between Pre-Intervention Thrombolysis and Primary Coronary Intervention: A Prospective Randomized Trial - Five-Year Results of the IMPORTANT Study -

Itoh

Fukami

Suzuki

et al. 2010

Circ J

View full text Add to dashboard Cite

“…12 Our results demonstrate that the TAT levels are also in- mg/L) are far greater than the TAT levels (1 to 2 jig/L).…”

Section: Discussionmentioning

confidence: 46%

Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication.

Tohgi

Takahashi

Chiba

et al. 1993

Stroke

View full text Add to dashboard Cite

Background and Purpose: We studied the activities of the coagulation-fibrinolysis system in the chronic stage of poststroke patients and the effect of antiplatelet medication on the system. Methods: We determined fibrinogen, antithrombin III, thrombin-antithrombin III complex, tissue plasminogen activator antigen, plasminogen activator inhibitor-1, plasmin-m plasmin inhibitor complex, and D-dimer in plasma from 153 poststroke patients in the chronic phase (ie, 33 patients not receiving antiplatelet medication, 78 patients receiving 200 mg/d ticlopidine, and 42 patients receiving 40 mg/d aspirin), and compared the results in control subjects and among the treatment groups.Results: The concentrations of fibrinogen, thrombin-antithrombin III complex, antithrombin III, plasmin-tv2 plasmin inhibitor complex, and tissue plasminogen activator were slightly but significantly increased in all treatment groups compared with control subjects (P<.01) but did not differ among the treatment groups. The plasminogen activator inhibitor-1 levels were significantly elevated in patients not receiving antiplatelet medication compared with control subjects (P<.01), whereas they were in the normal range and significantly lower in patients receiving ticlopidine or aspirin than in patients not receiving antiplatelet medication (P<.01). The plasminogen activator inhibitor-1 levels were significantly lower in patients whose platelet aggregation was inhibited by antiplatelet medication than in patients with uninhibited platelet aggregability (P<.05).Conclusions: These findings suggest that coagulation-fibrinolysis markers are mildly increased in poststroke patients in the chronic phase and that antiplatelet medication is effective in reducing the

show abstract

“…They are not fully understood but include increased procoagulant activity induced by pharmacological activation of plasminogen, local expression of procoagulant activity when the vessel is reperfused, presence of high shear forces that promote platelet deposition, and attenuation of physiological fibrinolytic activity after pharmacological thrombolysis 7 . Thus, recurrent thrombosis after coronary thrombolysis depends on a complex interaction between procoagulant factors associated with the atherosclerotic plaque, procoagulant activity induced by the residual thrombus, and paradoxical procoagulant activity which is promoted by pharmacological thrombolysis 8,9 . The interaction between thrombus‐bound thrombin and circulating blood may not only exert a prothrombotic stimulus through the activation of factor V but also by reducing endogenous thrombolytic potential via the induction of thrombin activatable fibrinolysis inhibitor (TAFI).…”

Section: Mechanisms Of Failure Of Thrombolysismentioning

confidence: 99%

Anti-Thrombotic, anti-platelet and fibrinolytic therapy: Current management of acute myocardial infarction

Helft¹,

Worthley

2001

Heart, Lung and Circulation

View full text Add to dashboard Cite

Thrombin/Antithrombin-Iii Complex Level as Early Predictor of Reocclusion After Successful Thrombolysis

Cited by 51 publications

References 4 publications

Comparison of Long-Term Prognostic Evaluation Between Pre-Intervention Thrombolysis and Primary Coronary Intervention: A Prospective Randomized Trial - Five-Year Results of the IMPORTANT Study -

Comparison of Long-Term Prognostic Evaluation Between Pre-Intervention Thrombolysis and Primary Coronary Intervention: A Prospective Randomized Trial - Five-Year Results of the IMPORTANT Study -

Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication.

Anti-Thrombotic, anti-platelet and fibrinolytic therapy: Current management of acute myocardial infarction

Contact Info

Product

Resources

About